Trial reportHeart and vessels2014
Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance.
Trial report in Heart and vessels, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Brazilian Society of Cardiology Guideline on Myocarditis - 2022.Arquivos brasileiros de cardiologia · 2022Guideline
- Prednisone and azathioprine in patients with inflammatory cardiomyopathy: systematic review and meta-analysis.ESC heart failure · 2020Pooled it
- Intravenous immunoglobulin for presumed viral myocarditis in children and adults.The Cochrane database of systematic reviews · 2020Pooled it
- Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: A systematic review and meta-analysis.Scientific reports · 2019Pooled it
- Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis.Heart failure reviews · 2018Pooled it
- Post-viral myocarditis.Heart failure reviews · 2026Review
- The clinicopathologic features of fulminant myocarditis.Journal of advanced research · 2026Article
- Multimodality Imaging in Eosinophilic Myocarditis: A Rare Cause of Heart Failure.Journal of cardiovascular development and disease · 2025Review
- Deep insight into cytokine storm: from pathogenesis to treatment.Signal transduction and targeted therapy · 2025Review
- Review
- Therapeutic frontiers in viral myocarditis: targeting inflammation, viruses, oxidative stress, and myocardial repair.Frontiers in immunology · 2025Review
- A comparative review of myocarditis in pediatrics versus adults: pathogenesis, diagnosis, and management.Frontiers in immunology · 2025Review
- Update on Myocarditis: From Etiology and Clinical Picture to Modern Diagnostics and Methods of Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- Optimising the ECMO treatment regimen increases the survival rate for adult patients with acute fulminant myocarditis: A single-centre retrospective cohort study.Frontiers in medicine · 2023Article
- Successful treatment of fulminant myocarditis with intra-aortic balloon pump counterpulsation combined with immunoglobulin and glucocorticoid in a young male adult.Frontiers in cardiovascular medicine · 2022Article
- Effect of gamma globulin combined with creatine phosphate on viral myocarditis.American journal of translational research · 2021Article
- Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis.European heart journal · 2020Article
- Successful Treatment of Acute Fulminant Eosinophilic Myocarditis in a Patient with Ulcerative Colitis Using Steroid Therapy and Percutaneous Cardiopulmonary Support.Internal medicine (Tokyo, Japan) · 2019Article
- Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis.Science China. Life sciences · 2019Review
- Cardiac Autoimmunity: Myocarditis.Advances in experimental medicine and biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous immunoglobulin (IVIG) therapy has been used to treat several autoimmune or inflammatory diseases. We conducted a clinical trial of immunoglobulin therapy for acute myocarditis. The study consisted of two projects: (1) a comparison of prognosis between patients treated with and those not treated with IVIG in a multi-center study; (2) analyses of inflammatory cytokines and blood cell profiles in a substudy. In (1), 15 patients were treated with IVIG (1-2 g/kg, over 2 days), whereas 26 were untreated. There was a statistically significant difference between the survival curves of the patients treated with IVIG and the survival curves of those not treated with IVIG. There was no significant difference between the IVIG-treated and untreated groups in terms of clinical parameters of the acute and chronic phases. In (2), 10 patients were treated with IVIG and 6 were untreated. In both groups, all of the data except for changes in the fraction of lymphocytes and the fraction of monocytes decreased due to the treatment or during the course. In patients in the IVIG group, the percentage of peripheral eosinophils was decreased and the percentage of peripheral monocytes was increased by this treatment when they were compared with the pretreatment data. Therefore, therapy with IVIG seems to be a promising treatment for acute myocarditis given that it improves the clinical course, which may be due to modulation of inflammatory cytokines and the peripheral leukocyte balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.